BMS Reports Long-Term Efficacy of Opdivo + Yervoy Combination in Advanced Melanoma with 57% Five-Year Survival Rate at ASCO 2019
Jun 05, 2019 09:13
CST Updated
09:13
Bristol-Myers Squibb
Biopharmaceutical and Nutritional Product R&D and Sales
June 05, 2019 /BioValleyBIOON/ -- Bristol-Myers Squibb (BMS) recently announced the latest study results evaluating the immunotherapy combination Opdivo + Yervoy (OY combination) for the treatment of advanced or metastatic melanoma at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago.
The 5-year analysis from the Phase I CA209-004 study represents the longest follow-up to date for the OY combination therapy in patients with previously treated or untreated advanced melanoma. The data showed: with a median follow-up of 43.1 months (range: 0.9–76.7), the overall survival (OS) rate remained stable at 57% (95% CI: 47–67), and the 3-year OS rate after treatment discontinuation was 56% (95% CI: 46–66).
The study also demonstrated that the OY combination yielded long-term survival outcomes regardless of BRAF or lactate dehydrogenase (LDH) status: the 4-year overall survival (OS) rates were 54% (95% CI: 41–65) in patients with BRAF wild-type tumors and 61% (95% CI: 38–77) in those with BRAF-mutant tumors. The overall safety profile of the OY combination in this study was consistent with previously reported findings in patients with advanced melanoma treated with the OY regimen.
Opdivo (Oudiwo, generic name: nivolumab) and Yervoy (ipilimumab) are both cancer immunotherapies (I-O) that harness the body’s own immune system to fight tumors by targeting distinct regulatory components of the immune system. Opdivo works by blocking the PD-1/PD-L1 pathway, while Yervoy targets and blocks CTLA-4.
Arvin Yang, Head of Melanoma and Genitourinary Cancers Research and Development at Bristol-Myers Squibb, stated, “These latest findings provide further support for the long-term scientific rationale behind using Opdivo in combination with Yervoy for the treatment of advanced melanoma. We will continue to evaluate the long-term survival benefits of the Opdivo-Yervoy combination in these patients, as it also yields valuable scientific insights into the impact of immuno-oncology therapies on this population.”(Bioon.com)